Scientific Publication

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis

author(s) Ferlazzo, G. - Mohr, E. - Laxmeshwar, C. - Hewison, C.
from UK Foreign, Commonwealth & Development Office (FCDO)
permalink open
themes
regions
  • Northern Europe
  • Europe
  • World
  • Southern Africa
  • Sub-Saharan Africa
  • Africa
  • Southern Asia
  • Asia
  • Western Asia
citation

Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: A retrospective cohort study. The Lancet Infectious Diseases. 2018;3099(18)

Publications and datasets provided via GARDIAN

Abstract

Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients have been unable to access the two drugs in combination. Médecins Sans Frontières has supported the use of combination bedaquiline and delamanid for people with few treatment options since 2016. We describe early safety and efficacy of regimens containing the bedaquiline and delamanid combination in patients with drug-resistant tuberculosis in Yerevan, Armenia; Mumbai, India; and Khayelitsha, South Africa. This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Open original